JS Elborn, F Blasi, PR Burgel… - European Respiratory …, 2023 - Eur Respiratory Soc
Recurrent and chronic bacterial infections are common in people with cystic fibrosis (CF) and contribute to lung function decline. Antibiotics are the mainstay in the treatment of …
F Saluzzo, L Riberi, B Messore, NI Loré, I Esposito… - Cells, 2022 - mdpi.com
Cystic Fibrosis (CF) is an autosomal recessive disease caused by mutations in the gene encoding for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein …
The availability of multiple publicly-available datasets studying the same phenomenon has the promise of accelerating scientific discovery. Meta-analysis can address issues of …
TH Hampton, R Barnaby, C Roche… - … of Physiology-Lung …, 2024 - journals.physiology.org
The combination of elexacaftor/tezacaftor/ivacaftor (ETI, Trikafta) reverses the primary defect in cystic fibrosis (CF) by improving CFTR-mediated Cl− and HCO3− secretion by airway …
K Brackenborough, H Ellis… - Seminars in Respiratory …, 2023 - thieme-connect.com
The threat of respiratory virus infection to human health and well-being has been clearly highlighted by the coronavirus disease 2019 (COVID-19) pandemic. For people with cystic …
TH Hampton, R Barnaby, C Roche, A Nymon… - bioRxiv, 2024 - biorxiv.org
The combination of elexacaftor/tezacaftor/ivacaftor (ETI, Trikafta) reverses the primary defect in Cystic Fibrosis (CF) by improving CFTR mediated Cl-and HCO3-secretion by airway …
Cystic fibrosis is the most common lethal genetic disease in the white population, affecting approximately 80 000 people worldwide. It is an autosomal recessive, monogenic, and …
Las infecciones bacterianas recurrentes y crónicas son frecuentes en pacientes con fibrosis quística (FQ), y contribuyen al deterioro de la función pulmonar. Los antibióticos constituyen …
Las infecciones bacterianas recurrentes y crónicas son frecuentes en pacientes con fibrosis quística (FQ), y contribuyen al deterioro de la función pulmonar. Los antibióticos constituyen …